The Latest Analyst Ratings for BioAtla
Portfolio Pulse from Benzinga Insights
BioAtla (NASDAQ:BCAB) has received positive analyst ratings in the last quarter, with 4 bullish and 1 somewhat bullish ratings. The company's average price target has increased by 60.0% from the previous average price target of $12.00 to $19.2.
August 04, 2023 | 11:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioAtla has received positive analyst ratings, which could potentially boost its stock price in the short term.
Analyst ratings often influence investor sentiment and can impact a company's stock price. In this case, BioAtla has received predominantly positive ratings, which could potentially lead to an increase in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100